In this video update, Uro-oncology Clinical Nurse Specialist Janet Forgenie explains how nurses can support patients undergoing radiopharmaceutical treatment for metastatic castrate-resistant prostate cancer (mCRPC).

Watch the video and download the accompanying slides to learn about:

  • The considerations for treatment selection in clinical practice to minimise the impact on patients' lives
  • Applying recent data to treatment sequencing in bone-dominant mCRPC
  • Educating and supporting patients during treatment so they know what to expect

 

Clinical Takeaways

  • Radiopharmaceuticals such as radium-223 and 177Lu-PSMA-617 offer a survival benefit to mCRPC patients as well as managing bone pain and QOL

  • They are able to deliver targeted radiation to prostate cancer cells, thereby minimising toxicity to normal healthy tissue

  • Real-world data support using 177Lu-PSMA in patients who previously received Ra-223

  • Nurses and patients should be aware of post-treatment precautions, but radiopharmaceuticals are an effective and manageable treatment option for mCRPC patients

 

Janet Forgenie works at University College Hospital London as a Uro-oncology CNS managing patients with organ confined disease as well as metastatic disease having chemotherapy, radiotherapy and immunotherapy treatments primarily for prostate but also with bladder and penile cancer. She has a specialist interest in penile cancer patients who undergo extensive treatment regimens with complex health care needs. Over the years as a uro-oncology CNS Janet has been involved in setting up patient support groups and information seminars for radiotherapy patients which have proven very successful. She has also been involved in an exercise pilot for prostate patients on hormone treatments to encourage exercise to help manage some of the unpleasant side effects from hormones, such as bone health, body image and weight gain. Her background of diagnostic urology has helped extensively in the management of prostate cancer patients, and as a nurse prescriber Janet feels this has been invaluable in the development of a truly independent nurse led service. Janet started her nursing career in Canterbury Kent, achieving her Nursing Diploma in 1994 and Degree in 1997. During her nursing career Janet has worked primarily within urology and oncology, and her current role as a Uro-oncology CNS that combines both specialities is ideal. Janet’s urology experience has been extensive over the past 26 years, working with benign urology as well as oncology urology. She has experience with diagnostic urology, urodynamics and continence and bladder function and has also been involved in pathway development and service development. Janet also has three years of oncology experience, one of which was spent in Australia working with chemotherapy patients and the other two working on an inpatient chemotherapy ward.

Janet Forgenie has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Astellas, Bayer

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
Endorsement
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU NURSES CONNECT

GU NURSES CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer, and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

conference-update Conference update
Oncology 
Highlights from ASCO 2025

Coming Soon: Expert insights on the latest data 

Experts
Prof. Mark Socinski, Dr Elizabeth Smyth, Dr Paolo Tarantino, Dr Domenica Lorusso, Prof. Gerhardt Attard
Endorsed by
Exon20group Biomarker Collaborative ICAN international cancer advocacy network
Lung Cancer Europe
  • clock 1 MIN
  • calendar May 2025

The oncogene-addicted NSCLC supported through an Independent Educational Grant from Bayer with all other updates supported by COR2ED
symposium Symposium
Oncology 
ER+/HER2- metastatic breast cancer: Highlights from ESMO Breast Cancer 2025 Satellite Symposium

Medical experts discuss treatment strategies and sequencing after ET + CDK4/6i for ER+/HER2- metastatic breast cancer

Experts
Prof. Wolfgang Janni, Prof. Sherko Kümmel, Prof. Michail Ignatiadis
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar May 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only
podcast Podcast
Hemostasis and bleeding disorders Oncology 
Serie de podcasturi referitoare la gestionarea trombozei

Experți de renume din domeniul medical își împărtășesc perspectivele. Navigați în secțiuni pentru a selecta un episod al podcastului 

Experts
Prof. Dimitrios Tsakiris, Dr Lars Asmis, Prof. Jerzy Windyga, Prof. Daniel Bolliger
  • download Downloadable
    Resources
  • clock 21 MIN
  • calendar May 2025

This educational programme is supported by an Independent Educational Grant from Viatris.
video Video
Oncology Hemato-oncology 
Optimising the sequence of novel therapies from early relapse in multiple myeloma

Improving the survival of patients with relapsed/refractory multiple myeloma

Experts
Prof. Hermann Einsele, Prof. Evangelos Terpos
  • download Downloadable
    Resources
  • clock 2 MIN
  • calendar May 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only
animated-video Animated Video
Oncology 
BRAF V600E mutated NSCLC: The evolving treatment landscape

Expert insights into personalised treatment strategies in BRAF-mutated NSCLC

Experts
Prof. Amanda Tufman
Endorsed by
BRAF Bombers ICAN international cancer advocacy network Biomarker Collaborative
Lung Cancer Europe
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar May 2025

This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. 
podcast Podcast
Oncology 
Tackling metastatic pancreatic ductal adenocarcinoma (mPDAC)

Chemotherapy strategies that matter

Experts
Prof. Shubham Pant, Prof. Efrat Dotan
Endorsed by
DiCE ICAN international cancer advocacy network
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar May 2025

Educational programme supported by an Independent Educational Grant from Ipsen USA